Skip to content

A clinical study to evaluate the effect and safety of B C CAPS in Abnormal vaginal discharge due to microbial infections

An Open label Clinical study to evaluate the efficacy and safety of B C CAPS manufactured by NUTRA GRACE in Abnormal vaginal discharge due to microbial infections

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032728
Enrollment
15
Registered
2021-04-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N898- Other specified noninflammatory disorders of vagina

Interventions

Intervention1: B C CAPS NIMBA BEEJA TAILA VAGINAL CAPSULES: Each liquid filled hard elating contains Proporietory Blend of Neem Seed Oils 500 mg. 2 capsules to be administered manually in vagina befo

Sponsors

NUTRA GRACE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18- 45 yrs 2. Subjects with presence of signs and symptoms such as irritation, soreness, dysuria, vulvovaginal inflammation (edema, erythema) and abdominal pain. 3. Subjects with confirmed laboratory diagnosis of abnormal vaginal discharge. 4. Subjects willing to give written informed consent and come for a regular follow up

Exclusion criteria

Exclusion criteria: 1. Allergy to neem products. 2. Pregnant subjects. 3. Patients who had taken oral or intravenous antifungal agents within 4weeks or used topical vaginal antifungal drugs within 1 week before enrollment. 4. Terminally ill patients or patients with severe cardiac, hepatic renal or cerebrovascular disease, malignancy, chronic uncon-trolled systemic disease e.g. hypertension, collagen disorders, etc or any other serious medical illness. 5. Patients who have participated in a new drug study in the past 3 months. 6. Any other condition that in the opinion of the investigator does not justify the patientâ??s participation in the study.

Design outcomes

Primary

MeasureTime frame
Change in microbiological parametersTimepoint: Baseline and Day 14

Secondary

MeasureTime frame
Change in Clinicianâ??s assessment of symptomsTimepoint: Baseline, Day 7 and Day 14;Change in Subjective assessment of symptomsTimepoint: Baseline and Day 1 to 14;Continuous monitoring for AEs and SAEsTimepoint: Day 1 to 14

Countries

India

Contacts

Public ContactMr Sunil Gupta

Pharexcel Consulting

info@pharexcelconsulting.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026